

Disclosures. Kirsten St. George, MAppSc, PhD, Akonni Biosystems (Other Financial or Material Support), ThermoFisher (Grant/Research Support), Zeptomatrix (Other Financial or Material Support, royalty generating collaborative agreement); others, no disclosures reported.

LB16. The Role of Adults in the Measles Outbreak in New York State Outside of New York City, 2018–2019

Elizabeth Dufort, MD¹; Dylan Johns, MS¹; Manisha Patel, MD, MS²; Manisha Patel, MD, MS²; Nina Ahmad, MD¹; Patricia S. Ruppert, DO, MPH³; Elizabeth Rausch-Phung, MD, MPH¹; Paul Gastanaduy, MD, MPH²; Paul Gastanaduy, MD, MPH¹; Robert McDonald, MD, MPH^{4,5}; Maria Souto, MPH³; Patrick Bryant, PhD^{5,6}; Kevin T. McKay, MPH³; Lissette McNulty, MSN, RN⁷; Nancy McGraw, LCSW, MBA, MPH⁸; Ada J. Huang, MD⁹; Rachel E. Wester, MPH, BSN, RN¹⁰; Kirsten St. George, MAppSc, PhD^{5,6}; Jamie N. Sommer, MS¹; Karen L. Southwick, MD, MSc¹¹; Dina Hoefler, PhD¹; Vanessa Landis, MPH¹; Eleanor Adams, MD¹; Eleanor Adams, MD¹; Stephanie Ostrowski, PhD, MPH¹; Toby R. Levin, PhD, MPH, CHES⁹; Irina Gelman, DPM, MPH, PhD⁷; Brad Hutton, MPH¹; Howard Zucker, MD¹; Debra Blog, MD, MPH¹; ¹New York State Department of Health, Albany, New York.; ²CDC, Atlanta, Georgia.; ³Rockland County Department of Health, Pomona, New York.; ⁴Centers for Disease Control and Prevention, New York.; ⁵State Department of Health, Atlanta, Georgia.; ⁶Wadsworth Center, New York.; ⁷Orange County Department of Health, Goshen, New York.; ⁸Sullivan County Public Health Services, Liberty, New York.; ⁹Westchester County Department of Health, New Rochelle, New York.; ¹⁰NYSDOH, Albany, New York.; ¹¹New York State Department of Health, New Rochelle, New York

Session: 294. Late Breaker Oral Abstract Session 2
Saturday, October 5, 2019: 1:55 PM

Background. The United States is experiencing the largest measles outbreak since elimination was declared in 2000, with the majority of cases in NYS reported in undervaccinated communities. The objective of this evaluation was to describe adult measles cases in the NYS measles outbreak outside of New York City (NYC).

Methods. We included all confirmed cases aged ≥18 years in NYS residents (excluding NYC) during October 1, 2018–July 25, 2019 that met the CSTE measles case definition. We defined measles cases attributable to adults as the sum of measles cases among adults and children who contracted disease directly from adults.

Results. Among 371 confirmed measles cases, the median age was 5.5 years (range: 1 day to 64 years); 79 (21%) were in adults, 4 (5%) of whom were born before 1957 (3 unvaccinated and 1 with unknown vaccine status). Among the 75 cases born during or after 1957, 65 (87%) were unvaccinated or had unknown vaccine status, while 3 had one dose and 7 had 2 doses of measles vaccine. Notably, 5 of 11 internationally imported measles cases were adults, and all were unvaccinated or had unknown vaccine status. During the first month of the outbreak, 26 of the 51 (51%) cases were attributable to adults; of the 26, 15 (58%) were in adults and 11 (42%) were in children who acquired infection from adults (Figure 3).

Conclusion. The majority of measles cases occurred in unvaccinated children emphasizing the importance of ongoing and focused efforts on pediatric vaccination. However, measles cases in unvaccinated adults played an important role in both importations and disease transmission early in the outbreak. These data strongly support current recommendations of 1 dose of measles, mumps, rubella vaccine (MMR) for most adults and 2 doses of MMR for adults traveling internationally and at high-risk such as those in outbreak areas, as determined by local/state public health.

Figure 1: Age of Confirmed Measles Cases by Measles Vaccination Status in New York State (excluding New York City), 2018–2019




Figure 2: Age of Confirmed Measles Cases by Rash Onset Date Over Time, New York State (excluding New York City), 2018–2019





Figure 3. Measles Cases by Age and Epidemiologic Linkage, New York State (excluding New York City), October 2018



Disclosures. Kirsten St. George, MAppSc, PhD, Akonni Biosystems (Other Financial or Material Support), ThermoFisher (Grant/Research Support), Zeptomatrix (Other Financial or Material Support, royalty generating collaborative agreement).

LB17. Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

Brenna Hughes, MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Durham, North Carolina

Session: 294. Late Breaker Oral Abstract Session 2
Saturday, October 5, 2019: 2:05 PM

Background. Primary CMV infection during pregnancy carries a high risk of fetal transmission with the potential for severe sequelae. There is no universally accepted method of preventing congenital CMV. Our objective was to evaluate whether CMV hyperimmune globulin (HIG) administered to women with primary CMV during pregnancy reduces congenital infection.

Methods. Multicenter randomized double-masked trial of women with a singleton gestation <24 weeks with primary CMV infection defined by the presence of either CMV IgM and IgG with low avidity or IgG seroconversion, as assessed at a central reference laboratory. Those with presumptive or confirmed evidence of fetal CMV were not eligible. Monthly infusions of HIG (100 units/kilogram) or placebo were given until delivery. The primary outcome was fetal loss or neonatal CMV infection defined as CMV by PCR or culture in urine or saliva within 3 weeks of birth, in amniotic fluid prior to delivery or in postmortem tissue. A sample size of 800 was planned to detect at least 30% reduction in the primary outcome with 90% power and type I error 5%.

Results. From 2012 to 2018, 206,111 pregnant women were screened; 712 (0.35%) had primary CMV infection; of whom, 399 (56%) were enrolled at 17 centers. The trial was stopped for futility at the recommendation of the Data and Safety Monitoring Committee due to a planned interim analysis that revealed complete enrollment was unlikely to demonstrate a significant outcome. Mean gestational age at randomization was 16.2 and 15.6 weeks in the HIG and placebo groups, respectively. Primary outcome data were available for 394 participants (98.7%). The primary outcome rate was 22.7% in the HIG group and 19.4% in the placebo group (relative risk [RR], 1.17; 95% confidence interval [CI], 0.80 to 1.72; p=0.42). Overall, there was no significant difference in the proportion of women with a side effect; however, those receiving HIG had a higher rate of headache (P = 0.05) and shaking chills (P = 0.03). The rate of preterm birth was 12.2% in the HIG group and 8.3% in the placebo group (RR, 1.47; CI 0.81 to 2.67; P = 0.2) (table). No statistical interactions were found in pre-specified subgroup analyses.

Conclusion. CMV HIG was not effective at decreasing risk of congenital CMV infection or fetal death among women with primary CMV infection in early pregnancy.

Primary and Secondary Outcomes	HIG (N=206)	Placebo (N=193)	Relative Risk (95% CI)	P Value
	no. (%)			
Primary outcome	46 (22.7)	37 (19.4)	1.17 (0.80 - 1.72)	0.424
Neonatal CMV infection	37	32		
Neonatal death without evidence of CMV	0	0		
Fetal death with evidence of CMV infection	6	3		
Fetal death without evidence of CMV	3	2		
Fetal/neonatal outcomes				
Fetal death	9 (4.4)	5 (2.6)	1.69 (0.58 - 4.97)	0.330
Neonatal death	1	0	-	-
Fetal growth restriction < 5th percentile	21 (10.7)	10 (5.3)	2.01 (0.97 - 4.16)	0.052
Head circumference < 3rd percentile	6 (3.1)	6 (3.2)	0.97 (0.32 - 2.95)	0.956
Maternal outcomes				
Any side effects	81 (39.3)	62 (32.1)	1.22 (0.94 - 1.60)	0.134
Preterm birth < 37 weeks	25 (12.2)	16 (8.3)	1.47 (0.81 - 2.67)	0.200

Disclosures. Brenna Hughes, MD, Merck (Consultant).